MedTrace Logo

Safety and Efficacy of RX-10100 to Treat Major Depressive Disorder

NCT01273376 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 314

Last updated 2013-11-19

No results posted yet for this study

Summary

The purpose of this study is to determine whether RX-10100 are effective in the treatment of Major Depressive Disorder (MDD).

Conditions

Interventions

DRUG

RX-10100

Extended-release tablet, taken twice daily for 8 weeks

Sponsors & Collaborators

  • Rexahn Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Christine Peterson, Ph.D · Rexahn Pharmaceuticals, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2011-09-30
Completion
2011-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01273376 on ClinicalTrials.gov